Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02950220
Title Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Kami Maddocks
Indications

B-cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Burkitt lymphoma

marginal zone B-cell lymphoma

lymphoplasmacytic lymphoma

mantle cell lymphoma

Therapies

Ibrutinib + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.